Abstract Purpose: Our aim was to examine whether active Ras and MycN cooperation contributes to the malignant phenotype of humanneuroblastoma with amplified MycN gene, an aggressive incurable tumor. Experimental Design: Human neuroblastoma LAN-1 cells, in which the MycN gene is amplified, were used to examine the impact of the Ras inhibitor farnesylthiosalicylic acid on cell growth, on the levels Ras and MycN proteins, and on profiles of gene expression. Results: We show that LAN-1 cells express relatively large amounts of MycN and active Ras-GTP. Inhibition of active Ras by farnesylthiosalicylic acid led to attenuation of the Raf-MEK-ERK and phosphoinositide 3-kinase-Akt-glycogen synthase-3 (GSK-3) pathways, to reduction in cyclin D1, phospho-retinoblastoma, and E2F, and to increase in the cyclin-dependent kinase inhibitor p27 and in retinoblastoma-binding protein-1, an inhibitor of E2F transcriptional activity. Ras inhibition by farnesylthiosalicylic acid or by a dominant-negative Ras also led to complete disappearance of MycN protein from the nuclei of LAN-1 cells. This was a result of blocking of Akt inactivation of GSK-3, leading to GSK-3-dependent phosphorylation with consequent proteosomal degradation of MycN. Loss of active Ras and of MycN in LAN-1cells was manifested in profiles of gene expression that could be expected from the loss of MycN transcriptional activity and of Ras signaling. These changes explain the farnesylthiosalicylic acid^induced inhibition of LAN-1 cell growth. Conclusions: Active Ras is needed to block MycN degradation, promoting cooperative Rasand MycN-dependent cell cycle progression in LAN-1cells. Ras inhibitors are therefore likely candidates for the treatment of advanced neuroblastoma characterized by high expression of MycN.
Cooperation between Ras and Myc is an important paradigm of cellular transformation (1) . The Ras proteins act essentially as extracellularly regulated relay systems. They are activated by extracellular signals that promote guanine-nucleotide exchange factor-mediated exchange of GDP for GTP on Ras (2) . The active GTP-bound Ras in turn activates a multitude of downstream effectors, including Raf-1, phosphoinositide 3-kinase (PI3K), and Ral-guanine-nucleotide exchange factors, which regulate cell proliferation, differentiation, survival, and death (3) . In many human tumors, Ras is chronically active (4) . This is largely attributable to activating mutations in Ras genes, but also to alterations in upstream components such as receptor tyrosine kinases that activate Ras (5) . The chronically active Ras contributes to uncontrolled cell growth and cell death, and-in cooperation with Myc, other oncogenes, and tumor suppressors-leads to malignant transformation.
The Myc proteins are short-lived nuclear transcription factors that regulate cell growth and apoptosis (1) . Defects in the Myc and the retinoblastoma/E2F pathways in conjugation with abnormalities in the Ras pathways are common in many human tumors (1, 6, 7) . Ras activation facilitates c-Myc functions in cell cycle progression and at the same time blocks the proapoptotic effects of c-Myc (1, 8) . c-Myc activity contributes to progression of the G 1 -S phase through induction of cyclin D/cyclin-dependent kinase (Cdk)-4 or cyclin E/Cdk2 or both, leading to the phosphorylation and inactivation of retinoblastoma family members and the liberation of E2F (1, 6) . Ras signaling also results in the activation of cyclin D/Cdk4 and the retinoblastoma/E2F pathway (1, 9 -11) . Such activities lead to enhanced cell proliferation. An important characteristic of the cooperation between Ras and c-Myc is conferred by the Ras-regulated stabilization of c-Myc. Active Ras promotes the stabilization and accumulation of newly translated c-Myc through Rasregulated enzymes that posttranslationally modify the NH 2 -terminal region of c-Myc (8) .
The NH 2 -terminal box 1 region of all Myc isoforms contains two key phosphorylation sites, Thr 58 and Ser 62 (8, 12) . Phosphorylation of these two sites has opposing effects on c-Myc stability and is carried out in both cases by kinases controlled by Ras (1, 8) . Ser 62 phosphorylation is catalyzed by extracellular signal-regulated kinase (ERK), and results in c-Myc stabilization. Phosphorylation of Thr 58 is catalyzed by glycogen synthase-3 (GSK-3) and targets c-Myc to the ubiquitin-proteasome protein degradation pathway. GSK-3 itself is negatively regulated by Akt, which phosphorylates and inactivates it (1) . Thus, Ras that promotes activation of Akt leads to inactivation of GSK-3 and elimination of c-Myc degradation (1) . This seems to result in accumulation of c-Myc in tumor cells characterized by chronically active Ras protein. More recent studies showed that protein phosphatase 2A dephosphorylates Ser 62 of c-Myc, whose phosphorylation stabilizes c-Myc, prior to its ubiquitination and degradation (13) .
Alterations in Myc that are common in many human tumors include mutation of Thr 58 , which prevents Myc degradation (8) , and Myc gene amplification, which leads to Myc overexpression (14, 15) . The latter is typical of the most aggressive stage IV neuroblastoma (16) . These tumors are characterized by amplified MycN genes, some of them having >100 copies (15) . The strong association between MycN gene amplification and aggressiveness of the disease, taken together with the aforementioned Ras-Myc cooperation, suggests that active Ras might contribute significantly to the malignant phenotype of advanced neuroblastoma. This possibility has not been examined up to now, probably because Ras gene mutations are rarely found in neuroblastoma (17) . Unlike the well-characterized mechanisms of cooperation between c-Myc and Ras, little is known about MycN-Ras interactions. However, because Ras might be chronically active even in the absence of Ras gene mutations, it is not unreasonable to assume that advanced neuroblastoma might exhibit significant amounts of active, GTP-bound Ras that cooperates with MycN. This possibility is supported by the knowledge that highly malignant neuroblastoma is characterized by high expression of the TRKB receptor, known to activate Ras pathways (18) , and its ligand brain-derived neurotrophic factor, which acts via autocrine loops to enhance neuroblastoma cell proliferation and survival (19) . Here we examined whether the cooperation between Ras and MycN contributes to the malignant phenotype of neuroblastoma. We used the cell line, LAN-1, which was derived from advanced human neuroblastoma and possess amplified MycN gene (18) .
Materials and Methods
Cell lines and reagents. LAN-1 cells and SHEP cells were grown in RPMI 1640 with 10% FCS. Farnesylthiosalicylic acid was prepared as described in detail previously (20, 21) . Hoechst dye 33258 was from Sigma-Aldrich (St. Louis, MO); the enhanced chemiluminescence kit was from Amersham (Arlington Heights, IL); mouse anti-pan-Ras antibodies (Ab-3) and mouse anti-MycN (Ab-1) were from Calbiochem (La Jolla, CA); rabbit anti-ERK1/2 antibodies, rabbit anti-cyclin D1 (M-20), rabbit anti-retinoblastoma (C-15), E2F1 (C-20), and rabbit anti-pMycN (Thr 58 /Ser 62 ) were from Santa Cruz Biotechnology (Santa Cruz, CA); mouse anti-phospho-ERK and rat anti-tubulin antibodies (AK-15) were from Sigma-Aldrich; rabbit anti-phospho-Akt (Ser 473 ) (4E2) was from Cell Signaling Technology (Beverly, MA) and rabbit anti-Raf-1 (C2), and mouse anti -retinoblastoma-binding protein 1 (RBBP1; clone LY11) were from Upstate Biotechnology (Lake Placid, NY). Peroxidase goat anti-mouse IgG, peroxidase goat anti-rabbit IgG, and peroxidase goat anti-rat IgG were from Jackson ImmunoResearch Laboratories (West Grove, PA); carbobenzoxy-Lleucyl-L-leucinal Z-LLL-CHO (MG132), LY294002, and U0126 were from Calbiochem.
Cell growth under farnesylthiosalicylic acid treatment. Cells were maintained at a constant temperature of 37jC in a humidified atmosphere of 95 air/5% CO 2 . They were plated at a density of 10 3 cells per well in 24-well plates and then treated with 50 Amol/L farnesylthiosalicylic acid or the vehicle (0.1% Me 2 SO). To determine whether farnesylthiosalicylic acid was toxic to cells, we used Hoechst 33258 (1 Ag/mL). Cells were incubated with the reagent for 5 minutes and the stained nuclei were visualized under a fluorescence microscope. Cell growth was estimated by direct counting of cells grown in RPMI 1640/10% FCS. LAN-1 cells (10 3 cells per well in 24-well plates) were incubated for the indicated time period in the presence of 0.1% Me 2 SO or 3 to 50 Amol/L farnesylthiosalicylic acid. After incubation, the cells were collected and counted.
Fluorescence in situ hybridization. The status of the MycN gene was determined by fluorescence in situ hybridization using the MycN probe (Vysis, Downers Grove, IL) as described previously (22) . The slides were analyzed using an Olympus BH2 fluorescence light microscope equipped with a Plan Apo objective 100Â/1.4 oil lens, an appropriate spectral filter (BH2-TFC1 Triple Band filter 4V,6-diamidino-2-phenylindole/FITC/TRITC), and a 100 W mercury arc lamp (22) .
Assay of Ras, Ras effectors, and cell cycle regulators. To examine the effect of farnesylthiosalicylic acid on Ras in the cultured cells, we plated LAN-1 cells at a density of 1.5 Â 10 6 cells per 10 cm dish and grew them in RPMI 1640/10% FCS. After 12 hours, farnesylthiosalicylic acid (25 or 50 Amol/L) or the vehicle (0.1% Me 2 SO) was added, and 48 hours later, the cells were homogenized in 300 AL homogenization buffer, and subjected to subcellular fractionation into 100,000 Â g pellet (P 100 ) and supernatant (S 100 ) as described (23) . Samples containing 30 Ag protein were subjected to SDS-PAGE, followed by immunoblotting with 1:2,500 pan-Ras antibodies and 1:7,500 peroxidase goat anti-mouse IgG, as described (23) . Ras protein bands were visualized by enhanced chemiluminescence . Alternatively, cells were lysed in 250 AL lysis buffer (23) and samples containing 50 Ag cell lysate protein (ERK, phospho-ERK, E2F1, p27 and tubulin) or 100 Ag protein (Akt, phospho-Akt, cyclin D1, retinoblastoma and RBBP1) were used for SDS-PAGE and immunoblotting with anti-ERK (1:2,000), anti-phospho-ERK (1:10,000), anti-Akt (1:1,000), anti-phospho-Akt (1:2,000), anti-cyclin D1 (1:1,000), anti-E2F1 (1:200), anti-p27 (1:1,000), anti-retinoblastoma (1:1,000), anti-RBBP1(1:500) or antitubulin (1:500) antibodies. Blots were then exposed to the appropriate secondary peroxidase-coupled IgG (1:5,000), and subjected to enhanced chemiluminescence (23) . Protein bands were quantified by densitometry with Image Master VDS-CL (Amersham Pharmacia Biotech, Piscataway, NJ) using TINA 2.0 software (Ray Tests).
Ras-GTP assays. Cells (1.5 Â 10 6 ) were plated in 10 cm dishes and farnesylthiosalicylic acid (25 or 50 Amol/L) was added 1 day later. The cells were then lysed, 48 hours after the drug treatment, in 0.5 mL of Ras-binding domain lysis buffer (24) containing 0.1 mmol/L orthovanadate. Lysates containing 500 Ag protein were analyzed for Ras-GTP by the glutathione S-transferase -Ras-binding domain pull-down assay followed by Western immunoblotting with pan anti-Ras antibodies as described previously (23) .
Raf-1 kinase assay. We determined Raf-kinase activity using a Raf-1 immunoprecipitation kinase cascade assay kit (Upstate Biotechnology). LAN-1 cells were plated (1.5 Â 10 6 cells in 10 cm dishes), and the next day, farnesylthiosalicylic acid (25 or 50 Amol/L) was added for 48 hours. The cells were then lysed in 0.5 mL of Raf-1 kinase assay kit lysis buffer. Raf-1 was immunoprecipitated from 1.5 mg lysate and assayed in the coupled kinase assay using myelin basic protein (Sigma) as a substrate and [g- Research. instructions. The amount of 32 P-labeled myelin basic protein thus formed was estimated in a scintillation counter.
PI3K assay. LAN-1 cells were treated with farnesylthiosalicylic acid, as described for the Raf-1 kinase assay. We lysed the cells with 0.5 mL of PI3K lysis buffer, immunoprecipitated the enzyme from 1.5 mg lysate with rabbit anti-PI3K p85 antibodies (Upstate Biotechnology), and assayed its activity with 1 mg/mL phosphatidyl inositol, 10 mmol/L ATP, and 5 ACi [g-32 P] ATP (23) . After extracting the lipids with chloroform/methanol, we separated them by TLC. Phospholipid markers were used for identification of the 32 P-labeled phosphatidyl inositol-3-phosphate product. The 32 P-labeled lipid products were visualized by overnight exposure on an X-ray film and the spots were quantified by TINA analysis (23) .
Confocal microscopy. We plated 2 Â 10 5 LAN-1 cells on glass coverslips and then treated them with 50 Amol/L farnesylthiosalicylic acid or the vehicle (0.1% Me 2 SO). Alternatively, the cells were cotransfected with plasmid DNA coding for Ras17N (1.4 Ag) or with a vector control (PCDNA3; 1.4 Ag) along with plasmid DNAs coding for green fluorescent protein (GFP; 0.6 Ag). The cells were fixed after 48 hours, or after 0, 6, 12, 18, 24, or 48 hours in the time course experiments, then permeabilized (25) . The cells were labeled with MycN antibodies by successive incubations with 1 Ag/mL anti-MycN antibodies, 5 Ag/mL biotin goat anti-rat IgG (Jackson Immuno Research), and 0.5 Ag/mL Cy3-streptavidin (Jackson ImmunoResearch) as detailed earlier (25) . For background staining, samples were stained in the absence of MycN antibodies. Staining intensity was analyzed with a Zeiss LSM 510 confocal microscope fitted with nonleaking green and red fluorescence filters (25) .
Sequence analysis of MycN gene box 1. RNA was extracted from LAN-1 cells using the SV Total RNA Isolation System (Promega, Madison, WI). RT-PCR was done with a Qiagen kit according to the instructions in the manual (Hilden, Germany), using the forward 5V -ATG CCG GGC ATG ATC TGC AAG AAC CC-3V primer and the reverse 5V-GGG CGG TGG AAC CGG CGG TTG GC GG-3V primer. The 368 bp RT-PCR product was subcloned into pGEM-T easy vector (Promega) and sequenced.
Gene expression profiling. All experiments were done using Affymetrix Human Focus oligonucleotide arrays, as described at http// www.affymetrix.com/support/technical/datasheets/human_data-sheet.pdf. Total RNA from each sample was used to prepare biotinylated target RNA. A complete description of the procedures is available at http://bioinf.picr.man.ac.uk/mbcf/downloads/GeneChip_Target_-Prep_Protocol_CRUK_v_2.pdf. The target cRNA was then generated from each sample according to the manufacturer's instructions, using an Affymetrix GeneChip Instrument System (Affymetrix, Santa Clara, CA). Spike controls were added to 10 Ag of fragmented cRNA prior to overnight hybridization. Arrays were then washed and stained with streptavidin-phycoerythrin before being scanned on an Affymetrix GeneChip scanner. Details of quality control measures can be found in Supplementary Table S3 . Genes were analyzed using the Mas 5 algorithm (see pivot data in Supplementary Table S1 ). Genes were filtered see Supplementary Table S2 ; samples of farnesylthiosalicylic acid -treated cells were compared with samples of untreated cells and differentially expressed genes were selected using t test with a threshold P value of 0.05. Genes were classified into functional groups using the GO annotation tool (http://apps1.niaid.nih.gov/David/upload.asp; ref. 26) .
Real-time PCR for the determination of RBBP1 expression levels. Extracts of total RNA (1 Ag) from cells treated for 48 hours with farnesylthiosalicylic acid (50 Amol/L) or vehicle (control) were reverse-transcribed in a total volume of 20 AL using the iSCRIPT cDNA Kit (Bio-Rad, Hercules, CA). The cDNA samples were then used for real-time PCR (Syber Green PCR Kit, Roche, Nutley, NJ). The PCR conditions and the primers used for RBBP1 and for the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase and HMBS are detailed in the supplement, real-time PCR (27) used as a control (Fig. 1A) . Separate experiments showed that significantly larger amounts of Ras and Ras-GTP are exhibited by LAN-1 cells than by SHEP cells (Fig. 1B) . The first indication that active Ras might be required for the malignant expression of the amplified MycN gene came from experiments with the Ras inhibitor farnesylthiosalicylic acid (20, 21) . This compound inhibited the growth of LAN-1 cells (Fig. 2A, B , and C). Under the conditions employed in these experiments, farnesylthiosalicylic acid had no cytotoxic effects, as indicated by Hoechst dye exclusion staining ( Fig. 2A and B) . Inhibition of LAN-1 cell growth by farnesylthiosalicylic acid was dosedependent with growth inhibition of 50% at 35 Amol/L farnesylthiosalicylic acid (Fig. 2C) . The Ras inhibitor also induced a significant change in cell morphology, manifested by flattening of the cells (Fig. 2C, inset) .
Over the concentration range at which farnesylthiosalicylic acid inhibited cell growth (50 Amol/L), it induced a small nonsignificant decrease of (mean F SD, n = 3) 24 F 9.1% in total Ras, a significant decrease of 30 F 6.9% (P < 0.01) in membrane-associated (P 100 ) Ras, and a stronger decrease of 47 F 8.5% (P < 0.01) in Ras-GTP (Fig. 3A) . The farnesylthiosalicylic acid -induced decrease in active Ras in the LAN-1 cells was accompanied by a decline in Ras signaling to Raf-1-MEK-ERK and to PI3K-Akt. Farnesylthiosalicylic acid inhibited Raf-1 activity by 24 F 10% (mean F SD, n = 3, P < 0.05) and caused a reduction of 36 F 6.6% (P < 0.05) in active pERK (Fig. 3A and B) . Inhibition of PI3K activity (by 41 F 13%, P < 0.05; Fig. 3C ) and reduction in active pAkt (by 59 F 7.4%, P < 0.001; Fig. 3A) were significantly stronger than the inhibition of Raf-1 activity and the reduction in pERK.
Next, we examined the effects of farnesylthiosalicylic acid on prominent regulators of the cell cycle. Within 24 to 48 hours farnesylthiosalicylic acid induced the down-regulation of cyclin D1 and of hyperphosphorylated retinoblastoma and E2F1, and concomitant up-regulation of the Cdk inhibitor p27 (Fig. 4A) . The decreases in cyclin D1, in phosphorylated retinoblastoma and in E2F1 at 48 hours (mean F SD, n = 3) were, respectively, 34 F 8%, 32 F 9%, and 44 F 17%. The increase in p27 at 48 hours was 1.3 F 0.15-fold (mean F SD, n = 3). Interestingly, in a gene profiling experiment (described below), we found that farnesylthiosalicylic acid induced a 4.3-fold increase in expression of the RBBP1, which inhibits E2F1 transcriptional activity (28) . This observation was confirmed by real-time PCR analysis, which disclosed a 1.4-fold increase in RBBP1 expression as a result of the farnesylthiosalicylic acid treatment. Using specific anti-RBBP1 antibodies, we found that farnesylthiosalicylic acid induced a 58 F 10% (mean F SD, n = 3) increase in expression of the RBBP1 protein (P < 0.05, Fig. 4B ). Taken together, the results can explain the Research. (Fig. 5A) show that LAN-1 cells expressed relatively large amounts of MycN, which were strongly down-regulated by 50 Amol/L farnesylthiosalicylic acid (65 F 8% decrease; mean F SD, n = 3, P < 0.01). Immunofluorescence analysis confirmed these results and showed that in the control cells, MycN was localized almost exclusively to the large nuclei (red, cy3 fluorescence), from which the drug treatment caused its complete removal (Fig. 5B) . The small amount of MycN that remained after the treatment was found in the cytosol (Fig. 5B) . To confirm that this effect was indeed related to the farnesylthiosalicylic acid -induced down-regulation of active Ras, we used Ras17N, a dominant-negative Ras isoform. The cells were cotransfected with vectors encoding GFP (to enable identification of the transfected cells) and Ras17N or with GFP and the empty vector control. Typical dual fluorescence images (green fluorescence, GFP; red fluorescence, MycN) from these experiments showed that Ras17N induced complete removal of MycN from the nuclei with no accumulation of MycN in the cytosol (Fig. 5C ), a finding indistinguishable from that of the effect of the Ras inhibitor farnesylthiosalicylic acid.
The farnesylthiosalicylic acid -induced mislocalization of MycN was time-dependent: a significant effect was observed not earlier than 18 hours after exposure, and was stronger 24 and 48 hours after the drug treatment (Fig. 6 ). Taken together, these experiments showed that the presence of large amounts of nuclear MycN in LAN-1 cells depends on the presence of active Ras-GTP, presumably because Ras stabilizes the MycN protein. Fig. 4 . A , farnesylthiosalicylic acid treatment induces time-dependent alterations in retinoblastoma, cyclin D1, E2F1, and p27 in LAN-1cells. LAN-1cells were plated (1.5 Â 10 6 cells/10 cm plate) and treated with the solvent or 50 Amol/L farnesylthiosalicylic acid for the indicated time periods. The cells were then lysed and subjected to SDS-PAGE and immunoblotting with anti-cyclin D1, anti-retinoblastoma, anti-E2F1, and anti-p27 antibodies. The experiment was repeated thrice and typical immunoblots visualized by enhanced chemiluminescence are shown. pRB, phosphorylated retinoblastoma; ppRB, hyperphosphorylated retinoblastoma. The decreases in cycline D1and in phosphorylated retinoblastoma at 48 hours were statistically significant (P < 0.05). The increase in p27 at 48 hours and the decrease in E2F1did not gain statistical significance. B, farnesylthiosalicylic acid induces an increase in the levels of RBBP1. LAN-1cells were plated (1.5 Â 10 6 cells/10 cm plate) and then treated with 0.1% Me 2 SO or 50 Amol/L farnesylthiosalicylic acid for 48 hours. The cells were lysed and subjected to SDS-PAGE and immunoblotting using anti-RBBP1antibodies. (Figs. 6 and 7 ) might be achieved, at least in part, by the Ras/PI3K/Akt pathway that prevents GSK-3-mediated phosphorylation of Thr 58 , a process that targets Myc to ubiquitin-mediated proteosomal degradation (1, 8) .
To examine this possibility, we incubated LAN-1 cells with farnesylthiosalicylic acid to down-regulate the active p-Akt protein (Fig. 3) and then determined the amount of p-MycN. The cells were exposed to farnesylthiosalicylic acid for 3 hours and then lysed, and the lysates were immunoblotted with specific anti-phospho-MycN (Thr 58 /Ser 62 ) antibodies. As shown in Fig. 7A , the Ras inhibitor induced a significant increase in p-MycN. This is consistent with the proposed mechanism whereby lack of Akt-mediated phosphorylation of GSK-3 promotes GSK-mediated phosphorylation of MycN. This notion was further supported by the finding that LiCl, which inhibits GSK-3 activity (29), blocked the farnesylthiosalicylic acid -induced increase in p-MycN (Fig. 7A, left) . In addition LY294002, which inhibits PI3K, induced a significant increase in p-MycN (Fig. 7A, right) . The MEK inhibitor U0126 induced a small insignificant decrease in p-MycN (Fig. 7,  right) . Notably, no apparent change in the total amount of MycN was observed in these experiments (Fig. 7A ) consistent with our earlier observation that MycN was down-regulated only 18 hours after farnesylthiosalicylic acid treatment (Fig. 6) . Thus, the observed farnesylthiosalicylic acid -induced phosphorylation of MycN preceded MycN down-regulation. This picture is consistent with a consecutive mechanism, previously known in the case of c-Myc, in which Thr 58 is phosphorylated and this targets c-Myc to proteosomal degradation. We therefore examined the effect of the proteasome inhibitor MG132 (30) on farnesylthiosalicylic acid -induced down-regulation of MycN. For these experiments, we chose a protocol in which the cells were incubated with farnesylthiosalicylic acid for a relatively long period (18 hours), at which MycN down-regulation was already apparent. Consistent with the results shown in Fig. 7 , farnesylthiosalicylic acid indeed induced a decrease in the amounts of both MycN and p-MycN (Fig. 7B) . At the same time, LAN-1 cells were incubated for 12 hours with farnesylthiosalicylic acid alone (to prime MycN phosphorylation and degradation), and then for a further 6 hours with farnesylthiosalicylic acid and MG132. Basal activity was determined in cells that were treated for 12 hours with the vehicle and for an additional 6 hours with MG132. As shown in Fig. 7B , MG132 blocked both the basal and the farnesylthiosalicylic acid -induced degradation of p-MycN. Thus, it seems that MycN, like c-Myc (1, 8) , was degraded by the proteasome. Accordingly, the observed downregulation of MycN by farnesylthiosalicylic acid was evidently an outcome of enhanced phosphorylation (Fig. 7A ) and proteasomal degradation of the protein (Fig. 7B) . These conclusions were strengthened by the observation that MG132 inhibited the farnesylthiosalicylic acid -induced disappearance of MycN from the nuclei of LAN-1 cells (Fig. 7C) .
Profiling of gene expression in farnesylthiosalicylic acidtreated LAN-1 cells. Next we examined whether the farnesylthiosalicylic acid -induced down-regulation of MycN in LAN-1 cells affects the expression of genes controlled by MycN. Because MycN regulates the expression of a large number of genes (31), we chose a comprehensive approach and gene expression analysis was done. We incubated LAN-1 cells with 50 Amol/L farnesylthiosalicylic acid or with the control vehicle for 18, 24, or 48 hours and then processed them for analysis of DNA microarray gene expression using the Affymetrix Human Genome Focus Array (8,500 sequences), as described in Materials and Methods. Analysis of the data using the Mas 5 algorithm (32) yielded a list of 4,799 ''valid genes'' (see Materials and Methods and supplementary Table S2 ), of which 211 showed significantly increased or decreased expression (control versus farnesylthiosalicylic acid, P < 0.05) at one or more time points during the drug treatment. Using the GO annotation tool (26) we then did functional clustering analysis (Fig. 8) , which enabled us to identify three large groups of genes whose expression was altered by the drug treatment.
These included genes involved in signal transduction, genes involved in nucleotide and nucleic acid metabolism, and genes involved in protein metabolism (Fig. 8) . Because MycN enhances the expression of genes involved in ribosome biogenesis and protein synthesis (31) , these kinds of alterations are clearly consistent with loss of MycN transcriptional activity. Further analysis of the gene expression profiles is needed and will be described elsewhere.
Discussion
MycN gene amplification is frequently detected in aggressive neuroblastoma (15, 33) . Strong expression of MycN protein, together with the presence of active Ras, could contribute to the malignant phenotype of these tumors as a result of cooperation between Ras and MycN. Up to now, this possibility has not been directly addressed. LAN-1 cells 6 cells/10 cm plate), and treated with 0.1% Me 2 SO or 50 Amol/L farnesylthiosalicylic acid for 18, 24, or 48 hours.We then processed the cells for RNA extraction and microarray profiling using the Human Genome Focus Array. Results of the functional clustering analysis as detailed in Materials and Methods. The three major groups of genes whose expression was altered after farnesylthiosalicylic acid treatment were genes involved in signal transduction, in nucleotide and nucleic acid metabolism, and protein metabolism.
this effect was confirmed by transfection of LAN-1 cells with dominant-negative Ras, which induced MycN downregulation (Fig. 5C ) that was indistinguishable from that induced by the Ras inhibitor. Thus, the amplified MycN gene by itself is not sufficient to maintain large amounts of MycN in the nuclei of LAN-1 cells, and Ras expression and activation seem to be required as well.
Consistent with the known mechanisms of c-Myc stabilization by oncogenic Ras (8), we found that down-regulation of Ras-GTP by farnesylthiosalicylic acid resulted in an increase in MycN phosphorylation, which was blocked by LiCl, an inhibitor of GSK-3 (29) . Because GSK-3 phosphorylates Thr 58 , which is required for Myc degradation (8) , this finding strongly suggested that the Ras inhibitor enhances the phosphorylation of Thr 58 of the MycN protein. In line with this suggestion, we found that the activity of PI3K and the amounts active p-Akt were down-regulated by Ras inhibition (Fig. 3) , thus preventing the inhibitory action of p-Akt on GSK-3 (1). Indeed, the PI3K inhibitor LY294002, like farnesylthiosalicylic acid, induced an increase in pMycN (Fig. 7) . Moreover, it seems that the Thr 58 -phosphorylated MycN, like Thr 58 -phosphorylated c-Myc (1, 8) , is degraded by the proteasome pathway because the proteasome inhibitor MG132 blocked both basal and farnesylthiosalicylic acidinduced MycN degradation in LAN-1 cells (Fig. 7) .
The farnesylthiosalicylic acid -induced facilitation of MycN degradation ( Fig. 7B and C) resulted in the disappearance of MycN from the nuclei of LAN-1 cells. This shows that it is sufficient to block Ras activity in LAN-1 cells in order to disrupt both Ras signals and MycN transcriptional activity. Treatment of LAN-1 cells with farnesylthiosalicylic acid indeed resulted in marked alterations in the cell cycle machinery proteins regulated by Ras and by Myc. The observed decrease in the amounts of cyclin D1, phospho-retinoblastoma, and E2F after farnesylthiosalicylic acid treatment (Fig. 4A) can be attributed to the known mechanisms of Ras regulation of cyclin D1/Cdk4 (1, 9 -11), namely the Raf-MEK-ERK cascade, shown to promote increased expression of cyclin D1 and assembling of the active cyclin D1/Cdk4 complex (37) , and the PI3K-Akt pathway, shown to prevent degradation of cyclin D1 by the Akt-mediated inhibitory phosphorylation of GSK-3, which in its unphosphorylated form tags cyclin D1 for ubiquitin/proteasome degradation (38) . The expected outcome of ERK and Akt inhibition (Fig. 3A) is then the downregulation of cyclin D1 (Fig. 4A) . This, together with the increase in p27 that blocks cyclin E/Cdk2 activity, would seem to account for the decrease in hyperphosphorylated retinoblastoma (Fig. 4A) , because both the initial cyclin D1/ Cdk4-dependent phosphorylation and the subsequent cyclin E/Cdk2-dependent phosphorylation of retinoblastoma would be prevented. This would lead in turn to reduction in the expression of E2F (Fig. 4A) .
In addition to the decrease in E2F observed in the farnesylthiosalicylic acid -treated cells, we observed a significant increase in the expression of RBBP1. This protein, known as a pocket protein of retinoblastoma, acts as an adaptor that recruits histone deacetylase to a complex with mSIN3. Association of RBBP1-histone deacetylase-mSIN3 complex with the retinoblastoma pocket results in the inhibition of E2F transcriptional activity (28). Altogether, it seems then that farnesylthiosalicylic acid -treated LAN-1cells enter a phase in which positive effectors of cell cycle progression are downregulated and negative effectors are up-regulated.
The mechanism of the farnesylthiosalicylic acid -induced increase in p27 in LAN-1 cells is not yet clear. It is not associated with the tumor suppressors p73 and p53, which would up-regulate p27 expression, because LAN-1 cells do not express p73 or p53 (39) . The mechanism of RBBP1 upregulation by farnesylthiosalicylic acid seems to be associated with the direct inhibition of Ras. Activated K-Ras was recently shown to down-modulate the formation of retinoblastoma/ RBBP1 complex by reducing RBBP1 gene expression (40) . These experiments, which show that Ras signaling attenuates RBBP1 expression, are in line with our present observation that Ras inhibition induced up-regulation of RBBP1.
Finally, the farnesylthiosalicylic acid -induced loss of active Ras and of MycN protein in LAN-1 cells was clearly manifested in profiles of gene expression that could be expected from the loss of MycN transcriptional activity and of Ras signaling (31) . For example, we observed changes in the expression of genes that are involved in ribosome biogenesis and protein synthesis (Fig. 8) . These findings are in line with the results of a recent analysis of gene expression in Ras-transformed cells, Myctransformed cells, and a variety of human tumor cells (41) . The analysis showed that the profiles of gene expression in tumors with high expression of c-Myc are consistent with the profiles in tumors that express dysfunctional Ras (41) . This is apparently due to the fact that both types of tumors exhibit activated Ras (41) . The accumulated findings, taken together with the present experiments, suggest that Ras inhibitors that cancel the cooperation between Myc and Ras are valuable candidates for the treatment of human tumors with high expression of Myc, such as neuroblastoma type III.
